MedTrace Logo

Radiosurgery and Avastin for Recurrent Malignant Gliomas

NCT01017250 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2014-02-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the central nervous system (CNS) toxicity in patients with recurrent malignant gliomas treated with concurrent Avastin and stereotactic radiosurgery (SRS).

Conditions

  • Malignant Glioma

Interventions

RADIATION

Stereotactic Radiosurgery (SRS)

Tumor Volume \< 2.0cm receives 24 Gy in 1 fraction Tumor Volume 2.0-2.9cm receives 18 Gy in 1 faction Tumor Volume 3.0-4.9cm receives 25 Gy in 5Gy/fraction

DRUG

Bevacizumab

Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS

Sponsors & Collaborators

Principal Investigators

  • John Kirkpatrick, MD, PhD · Duke University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-03-31
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01017250 on ClinicalTrials.gov